The Alton Ochsner Medical Foundation serves as the fiscal and administrative agent of Ochsner CCOP. The CCOP is composed of three major components: the Ochsner Clinic and Ochsner Foundation Hospital in New Orleans; Children's Hospital in New Orleans: Hattiesburg Clinic in Hattiesburg, MS: and two smaller affiliates: South Louisiana Medical Center in Houma, and the Mississippi Gulf Coast Component in Gulfport and Biloxi, MS. The Ochsner CCOP is an experienced clinical research unit having been one of the originally funded CCOP's. This CCOP combines the resources of a major medical center (the Ochsner Clinic) and teaching hospital (the Ochsner Foundation Hospital) with urban and rural medical centers with involvement of community oncologists in the true spirit of the CCOP RFA. The CCOP as a whole sees over 2500 previously untreated cancer cases per year making it a major resource for both clinical trials and cancer control studies. The CCOP utilizes the NCCTG as its primary research base. The NCCTG as a whole has an inter-group agreement to utilize selected ECOG protocols. The secondary CCOP research bases utilized are NSABP, GOG, and RTOG. The CCOP has also signed an affiliation agreement with the M.D. Anderson Comprehensive Cancer Center. The CCOP plans to primarily utilize the MDA cancer control protocols and selected non-conflicting clinical trials. Children's Hospital utilizes POG as their sole research base. This broad spectrum of carefully selected research bases gives the CCOP a full range of protocol availability. The data management has been simplified by computerization which in turn enhances quality control.
The specific aims of the Ochsner CCOP are to involve practicing physicians in cancer treatment and cancer control research. We will accomplish these specific aims in three ways: 1. Networking with key institutions in Louisiana - (The Ochsner Clinic, Children's Hospital of New Orleans, and South Louisiana Medical Center in Houma) and southern Mississippi (Hattiesburg Clinic and the Gulf Coast Affiliate in Biloxi and Gulfport). 2. Networking with a major HMO - The Ochsner Health Plan and the Ochsner Clinic have six primary care satellite clinics in suburban New Orleans. 3. Networking with an experienced multidisciplinary team of physicians, oncology nurses, and data managers.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA035272-05
Application #
3557685
Study Section
(SRC)
Project Start
1983-09-01
Project End
1990-05-31
Budget Start
1988-06-01
Budget End
1989-05-31
Support Year
5
Fiscal Year
1988
Total Cost
Indirect Cost
Name
Ochsner Clinic Foundation
Department
Type
DUNS #
City
New Orleans
State
LA
Country
United States
Zip Code
70121
Himelstein, Andrew L; Foster, Jared C; Khatcheressian, James L et al. (2017) Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial. JAMA 317:48-58
Pachman, Deirdre R; Qin, Rui; Seisler, Drew et al. (2016) Comparison of oxaliplatin and paclitaxel-induced neuropathy (Alliance A151505). Support Care Cancer 24:5059-5068
Gonsalves, Wilson I; Mahoney, Michelle R; Sargent, Daniel J et al. (2014) Patient and tumor characteristics and BRAF and KRAS mutations in colon cancer, NCCTG/Alliance N0147. J Natl Cancer Inst 106:
Barton, Debra L; Thanarajasingam, Gita; Sloan, Jeff A et al. (2014) Phase III double-blind, placebo-controlled study of gabapentin for the prevention of delayed chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy, NCCTG N08C3 (Alliance). Cancer 120:3575-83
Leal, Alexis D; Qin, Rui; Atherton, Pamela J et al. (2014) North Central Cancer Treatment Group/Alliance trial N08CA-the use of glutathione for prevention of paclitaxel/carboplatin-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled study. Cancer 120:1890-7
Huang, Jocelin; Nair, Suresh G; Mahoney, Michelle R et al. (2014) Comparison of FOLFIRI with or without cetuximab in patients with resected stage III colon cancer; NCCTG (Alliance) intergroup trial N0147. Clin Colorectal Cancer 13:100-9
Province, M A; Goetz, M P; Brauch, H et al. (2014) CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations. Clin Pharmacol Ther 95:216-27
Sticca, Robert P; Alberts, Steven R; Mahoney, Michelle R et al. (2013) Current use and surgical efficacy of laparoscopic colectomy in colon cancer. J Am Coll Surg 217:56-62; discussion 62-3
Barton, Debra L; Burger, Kelli; Novotny, Paul J et al. (2013) The use of Ginkgo biloba for the prevention of chemotherapy-related cognitive dysfunction in women receiving adjuvant treatment for breast cancer, N00C9. Support Care Cancer 21:1185-92
Lavoie Smith, Ellen M; Barton, Debra L; Qin, Rui et al. (2013) Assessing patient-reported peripheral neuropathy: the reliability and validity of the European Organization for Research and Treatment of Cancer QLQ-CIPN20 Questionnaire. Qual Life Res 22:2787-99

Showing the most recent 10 out of 72 publications